| pubmed-article:15712293 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C0220806 | lld:lifeskim |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C0599748 | lld:lifeskim |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C0008565 | lld:lifeskim |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C0392762 | lld:lifeskim |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:15712293 | lifeskim:mentions | umls-concept:C1568927 | lld:lifeskim |
| pubmed-article:15712293 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15712293 | pubmed:dateCreated | 2005-3-1 | lld:pubmed |
| pubmed-article:15712293 | pubmed:abstractText | A quantitative bioanalytical method involving chemical derivatization, solid phase extraction (SPE) and high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) was developed for the determination of 4-fluorobenzyl chloride (4FBCl) in human plasma. 4FBCl is a volatile and reactive molecule that is very unstable in human plasma. In order to stabilize 4FBCl in plasma samples prior to storage, 4-dimethylaminopyridine (DMAP) was added, forming a stable quaternary amine salt derivative. A three-step weak cation-exchange SPE procedure was then employed to remove excess DMAP. The plasma extracts were analyzed by HPLC/MS/MS using a TurboIonspray interface and multiple reaction monitoring. Unlike 4FBCl, the quaternary amine derivative shows excellent sensitivity in electrospray mass spectrometry. The method was validated over a concentration range of 0.5-500 ng/mL using 45 microL of plasma. The maximum within-run and between-run precision observed in a three-run validation for quality control (QC) samples was 12.5 and 7.6%, respectively. The maximum percentage bias observed at all QC sample concentrations was 11.9%. The method has proven to be robust and compatible with high-throughput bioanalysis. | lld:pubmed |
| pubmed-article:15712293 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15712293 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15712293 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15712293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15712293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15712293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15712293 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15712293 | pubmed:issn | 0951-4198 | lld:pubmed |
| pubmed-article:15712293 | pubmed:author | pubmed-author:CyronakMatthe... | lld:pubmed |
| pubmed-article:15712293 | pubmed:author | pubmed-author:KratzJohnJ | lld:pubmed |
| pubmed-article:15712293 | pubmed:author | pubmed-author:YangEricE | lld:pubmed |
| pubmed-article:15712293 | pubmed:author | pubmed-author:WangSherryS | lld:pubmed |
| pubmed-article:15712293 | pubmed:author | pubmed-author:BowenChesterC | lld:pubmed |
| pubmed-article:15712293 | pubmed:author | pubmed-author:DunbarJacob... | lld:pubmed |
| pubmed-article:15712293 | pubmed:copyrightInfo | Copyright 2005 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:15712293 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15712293 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:15712293 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15712293 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15712293 | pubmed:pagination | 759-66 | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:meshHeading | pubmed-meshheading:15712293... | lld:pubmed |
| pubmed-article:15712293 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15712293 | pubmed:articleTitle | Trapping 4-fluorobenzyl chloride in human plasma with chemical derivatization followed by quantitative bioanalysis using high-performance liquid chromatography/tandem mass spectrometry. | lld:pubmed |
| pubmed-article:15712293 | pubmed:affiliation | Worldwide Bioanalysis, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharm, 709 Swedeland Rd., King of Prussia, PA 19406, USA. eric.y.yang@gsk.com | lld:pubmed |
| pubmed-article:15712293 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15712293 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
| pubmed-article:15712293 | pubmed:publicationType | Validation Studies | lld:pubmed |
